Search
Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15740InvestigationalIn humans, OM-MSCs are derived from the olfactory mucosa which is collected in vivo through rhinoscopy techniques and nasal forceps.
Norclozapine
go.drugbank.com/drugs/DB05766InvestigationalACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.
Synonyms: N-DesmethylclozapineTD-2749
go.drugbank.com/drugs/DB05905ExperimentalTD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders
Bizalimogene ralaplasmid
go.drugbank.com/drugs/DB16113InvestigationalBizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related
Eflepedocokin alfa
go.drugbank.com/drugs/DB16366Investigational[A225706, L27661] It is being developed by Evive Biotech (previously known as Generon BioMed Inc).[L27666]
OTL-201
go.drugbank.com/drugs/DB17652ExperimentalOTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). … It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.[L45973]
beta-Alanine
go.drugbank.com/drugs/DB03107Investigationalbeta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].
4'-Methylene-5,8,10-trideazaaminopterin
go.drugbank.com/drugs/DB05616InvestigationalCH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier
MK-0354
go.drugbank.com/drugs/DB05939InvestigationalMK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.